Biolegend, 592224, Cell-Vive™ GMP Recombinant Human FGF-4 (carrier-free)
50microg
Catalog Number: 592224
Send an RFQ.
Category
Loading…
| Source | Human FGF-4, amino acids Ser54-Leu206 (Accession# P08620) was expressed in E. coli. |
|---|---|
| Molecular Mass | The 153 amino acid recombinant protein has a predicted molecular mass of approximately 19.7 kD. The non-reduced and DTT-reduced protein migrates at approximately 19.7 kD by SDS-PAGE. The predicted N-terminal amino acid is Serine. |
| N-terminalSequence Analysis | Ser-Leu-Ala-Arg-Leu-Pro-Val-Ala-Ala-Gln |
| Purity | ≥ 95%, as determined by Coomassie stained SDS-PAGE |
| Formulation | Protein was lyophilized from 0.1 μm filtered solution containing PBS. |
| Endotoxin Level | Less than or equal to 0.1 EU per μg of protein as determined by LAL method. |
| Residual Host Cell Protein Content | ≤ 0.500 ng/μg by ELISA |
| Concentration | 50 μg and 500 μg sizes are lyophilized |
Unless otherwise stated, the minimum order amount is USD 1,000.
For orders below USD 1,000, an additional handling fee may apply, or we may arrange local delivery / local handover where available.
All quotations are subject to final confirmation, including product availability, lead time, batch information, shipping cost, and applicable export or handling requirements.
For quotation requests, please send an RFQ from website or contact:
Please send inquiries directly to us in the “To” field. Emails sent via BCC, mass mailing, or with unrelated recipients may be automatically filtered and will not be processed.
| Storage & Handling |
|---|
| Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at - 20°C or colder until the expiration date. Reconstitute lyophilized protein in sterile PBS. Before reconstitution, make sure sterile PBS and product are at room temperature. Quickly spin the vial or gently tap down on the vial to make sure the lyophilized product is at the bottom of the vial before opening. Use aseptic techniques to add the required volume of reconstitution buffer (sterile PBS) to the vial, to obtain the recommended stock concentration 250 μg/mL. Close the vial and leave at ambient temperature for 15-20 minutes. Then gently invert the vial several times or until all of the lyophilized product dissolves. Leave the vial at room temperature for another 15 minutes. If small particulates are still observed after 15 minutes, incubate at room temperature for an additional 30 minutes and leave the vial at 2°C - 8°C overnight. Next day, invert the vial several times or gently pipette the solution up and down before use. If needed, transfer the reconstituted stock solution to a sterile container for additional dilution to no less than 100 μg/mL. Small working aliquots in polypropylene tubes can be made after reconstitution and store the vials at -20°C or lower. Avoid freeze/ thaw cycles. Carrier protein such as 0.2 - 1% endotoxin-free BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to two weeks or stored at -20°C or colder for up to 3 months. |
| Activity | The ED50 is 0.2-1 ng/mL as determined by a dose-dependent stimulation of NIH3T3 cell proliferation. |
|---|
| Application | Bioassay |
|---|
| Application Notes | Our lyophilized proteins are validated in-house to maintain activity after shipping at ambient temperature and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at [email protected]. |
|---|
| Application References(PubMed link indicates BioLegend citation) | Qi S, et al. 2019. Small. 15:e1804332. PubMed |
|---|
| Disclaimer | BioLegend Cell-Vive™ GMP Recombinant proteins are for research use only. Suitable for ex vivo cell processing. Not for injection or diagnostic or therapeutic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products. |
|---|
| Structure | Growth factor |
|---|
| Distribution | Expression of FGF-4 is highly restricted to undifferentiated stem cells. |
|---|
| Function | FGF-4 is a mitogenic, angiogenic, and survival factor. It is involved in cell proliferation and differentiation in embryonic development processes. N-glycosylation may negatively regulate FGF-4 activity. |
|---|
| Interaction | Precardiac myoblasts, megacariocytes, neural stem cells. |
|---|
| Ligand/Receptor | FGFR-I, IIIc; FGFR-2, IIIc; FGFR-3, IIIc, FGFR-4. |
|---|
| Bioactivity | Human FGF-4 induces the proliferation of NIH3T3 cells. |
|---|
| Antigen References | Konishi H, et al. 1996. Oncogene. 13:9. Sun X, et al. 2000. Nat Genet. 25:83-6. Yamamoto H, et al. 2002. Oncogene. 21:899-908. Kosaka N, et al. 2006. FASEB J. 20:1484-5. Kosaka N, et al. 2009. Dev. Dyn. 238:265-76. Arao T, et al. 2013. Hepatology. 57:1407-15. Itoh N and Ohta H. 2013. Front. Physiol. 4:247. |
|---|
| Gene ID | 2249 |
|---|
| UniProt | View information about FGF-4 on UniProt.org |
|---|
| Other Names | Fibroblast Growth Factor 4 (FGF-4), Heparin-Binding Growth Factor 4 (HBGF-4), HST-1, K-FGF, KS3, Kaposi Sacrcoma Oncogene, Heparin Secretory Transforming Protein 1 (HSTF-1) |
|---|
